January 25
2021
Trajan Shipley
share
30th November 2020
Consumer, Health & Environment Covid-19

EMA endorses statement calling for COVID-19 vaccine trials to continue beyond necessary time

The European Medicines Agency (EMA) has endorsed a statement by the International Coalition of Medicines Regulatory Authorities urging all relevant stakeholders to continue COVID-19 vaccine trials and data gathering efforts beyond the interim or final analysis for regulatory approval purposes.

The statement highlights that continued follow-up can provide important additional and more precise information on longer-term safety and efficacy against specific aspects of COVID-19, recommending these trials to continue with a follow-up period of at least of one year or more.

The European Commission presented its COVID-19 Vaccines Strategy in June 2020, as reported here by EU Law Live, and has signed contracts with pharmaceutical c

×

Your privacy is important for us

We use cookies to improve the user experience. Please review privacy preferences.

Accept all Settings

Check our privacy policy and cookies policy.

Cookies